Merakris Therapeutics is a North Carolina-based biotech company focused on regenerative medicine, specifically wound care for indications like diabetic foot and venous stasis ulcers. Merakris aims to develop effective therapies that require fewer treatments and improve patient outcomes while reducing healthcare costs. Instead of using whole cells, they utilize cell-derived signaling proteins and nano vesicles to promote healing. Currently, they are investigating the use of amniotic fluid exosomes and soluble proteins to activate the epithelial to mesenchymal transition and mesenchymal to epithelial transition, supporting early- and late-stage healing and keratinization. They’ve also developed an amniotic stem cell co-culture platform for the creation of targeted therapeutic formulations.

Merakris Therapeutics

We're Merakris Therapeutics, of course we're going to be exhibiting our Opticyte products at Vision Expo East on Friday. 

We're Merakris Therapeutics, of course we're going to be at booth P1846.

#VisionExpo #VisionEast2024 #DryEyes #Amnion #Cornea #CornealDefects #DryEyeDisease #AutologousSerumTears #AmnioticMatrix

Safety and efficacy of acellular human amniotic fluid and membrane in the treatment of non-healing wounds in a patient with chronic venous insufficiency

Merakris and Dept. of Veterans Affairs Sign CRADA Agreement - GlobeNewswire

Merakris Therapeutics Introduces Dermacyte® AC Matrix: A Lyophilized Amnion Chorion Allograft - GlobeNewswire

Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program - GlobeNewswire

 Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations 


				
					Merakris Therapeutics Announces Open Enrollment for Phase II Clinical Trial of Subcutaneous Injection Drug for the Treatment of VLU
					Read More
				
			

We are excited to announce Dermacyte AC Matrix: a Lyophilized Amnion Chorion Membrane.  Learn more about Dermacyte AC Matrix innovation at our booth this week at Symposium on Advanced Wound Care (SAWC) Fall in Las Vegas October 2-5! Read more at the link below.

https://lnkd.in/emjvb8zz


              Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations - Merakris Therapeutics
            

Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care - Yahoo Finance

Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid - Yahoo Finance

 Merakris Announces Nationwide At-Your-Door Autologous ... 

We are delighted to announce that enrollment is now open for Part 2 of our Phase 2 multicenter, clinical trial (NCT04647240) for our investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid. We are also excited to share that we filed an intermediate Expanded Access Protocol (EAP) with the US Food and Drug Administration (FDA) to provide expanded access to patients, which will be granted on a case-by-case basis in collaboration with qualified research centers.

Read the Press Release Here: https://lnkd.in/ejDJyGQK

Learn more about Merakris Therapeutics, Inc. Here: https://lnkd.in/e5yeNhQj

 Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte ... 

Comparative Analysis of Co-Cultured Amniotic Cell-Conditioned Media with Cell-Free Amniotic Fluid Reveals Differential Effects on Epithelial-Mesenchymal Transition and Myofibroblast Activation


				
					Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
					Read More
				
			

Merakris Therapeutics Announces Open Enrollment for Phase - GlobeNewswire

 Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial 

 Merakris Therapeutics Announces Open Enrollment for Phase II Clinical Trial of Subcutaneous Injection Drug for the Treatment of Venous Leg Ulcer 

 Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program 

expanded access policy

Cell-Free Amniotic Fluid and Regenerative Medicine: Current Applications and Future Opportunities

Greetings to all attendees of the Texas Optometric Association Summit! 👁️ Have you had the opportunity to see us yet? If you haven't, we warmly invite you to stop by Booth 608. We're eager to share how our innovative products can enhance the care you provide to your patients, as well as offer significant benefits to you as a professional. Don't miss out!

#TOA2024 #Austin #Amnion #RegenerativeOcularCare #DryEyeDisease #AutologousSerumTears #Cornea #AmnioticMembrane #Optometric #Optometrist #Optometric


				
					Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid
					Read More
				
			

Amniotic membrane for recurrent macular hole. 

This is a highly myopic patient with a recurrent myopic macular hole that did not close after vitrectomy, ILM peel and gas. I gave her the option to try an amniotic membrane with silicone oil, and she elected to proceed after discussing the risks, benefits and alternatives. 

These Optos true color RGB and red-green photos show that the amniotic membrane was in place on post-op day 1. Autofluorescence shows that there is still an underlying hole, but it is well-covered by the amniotic membrane. The Topcon Healthcare Triton Swept-Source OCT also confirms placement of the amniotic membrane on top of the macular hole. 

I used a 8mm disc amniotic membrane from Opticyte (Merakris Therapeutics, Inc.). The sterile packaging allowed us to easily transfer the tissue to the operating room back table. The amniotic membrane was carefully handled and cut into quarters. One quarter was able to be folded and placed through the 25 gauge trochar with an ILM forcep. Fluid air exchange was performed and the amniotic membrane stayed in place. 

The Opticyte membranes are particularly good because no chemical reagents are used and less irradiation is given which keep the vital components of the membrane active. GPO4EYES has special pricing on them, which our practice definitely appreciates for uses like this. 

I'll keep you guys updated on how the patient looks at the 1 month post-op visit!

#officesurgery #retina #vitrectomy
Benjamin Esque Tony Burns Joseph Bartel

If you’re not at booth P1846, then where you at?! 

We’re here at Vision Expo  East, and can’t wait to tell you how our products will benefit your clinic and patients! 

#VisionExpo #VisionEast2024 #Amnion #Cornea #CornealDefects #AmnioticMatrix #AutologousSerumTears

Excited to introduce a novel full thickness allograft - lyophilized amnion chorion - that has very unique properties.  Come see us at SAWC to learn more and check out the data we are excited to share with you.


				
					Merakris Therapeutics Introduces Dermacyte® AC Matrix: A Lyophilized Amnion Chorion Allograft
					Read More
				
			


              Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
            

 Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care 

Five North Carolina biotech companies making their mark - Labiotech.eu


              Use of amniotic membrane in hard-to-heal wounds: a multicentre retrospective study
            

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid - Yahoo Finance

 Wound Healing Technology Company Merakris Adds Two ... 

17 Biotech Companies in Research Triangle Park Helping People Live Healthier Lives - Built In

We're Merakris Therapeutics, of course we verify insurance benefits for your Opticyte patients. 

#VisionExpo #VisionEast2024 #Amnion #Cornea #CornealDefects #AmnioticMatrix

Merakris Therapeutics

Business:

About: